(Q45353776)

English

The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml

scientific article published in August 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Michele Lanciotti

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

author name string

Lorenzo Masieri

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Andrea Minervini

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Gianni Vittori

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Federico Lanzi

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Alberto Lapini

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Marco Carini

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sergio Serni

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

publication date

1 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

International Urology and Nephrology

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1031-1038

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

EPCA-2: a highly specific serum marker for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Serum markers for prostate cancer: a rational approach to the literature

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

The use of percent free prostate specific antigen for staging clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0135-Y

21 January 2018

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22315156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22315156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22315156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Free‐to‐total prostate‐specific antigen ratio as a predictor of non‐organ‐confined prostate cancer (stage pT3)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22315156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml

1 reference

https://pubmed.ncbi.nlm.nih.gov/22315156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://pubmed.ncbi.nlm.nih.gov/22315156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22315156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population

1 reference

https://pubmed.ncbi.nlm.nih.gov/22315156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11255-012-0135-Y

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45353776&oldid=2075548799"